Novartis AG put its VEGF-A ligand inhibitor, brolucizumab (RTH-258), to the test in neovascular age-related macular degeneration (nAMD) against Regeneron Pharmaceuticals Inc.'s cash cow, Eylea (aflibercept), and appeared to come up a winner.